AHA 2019 Pradhan was the discussant of the COLCOT trial. She put the results in the broader perspective of managing inflammation as a means to lower CV risk.
AHA 2019 Dr. Tardif summarizes the study design and results of the COLCOT trial, in which colchicine treatment was found to lower a composite endpoint in patients soon after MI.
AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.
CSI Paris Steven Hageman asks Cilie van 't Klooster about her study on the relationship between CRP levels and risk of incident cancer and recurrent CV events in subjects with stable CVD in the SMART-cohort.
Data of the BIOSTAT-CHF cohort suggest that the etiology of ID in worsening HF is multifactorial and may involve a combination of reduced iron uptake, impaired iron storage and iron loss.
A biomarker analysis in a subgroup of CANTOS participants shows that plasma levels of cytokines IL-6 and IL-18 are related to future CV risk both before and after treatment with canakinumab.
Data of a prospective cohort suggest that chronic systemic low-grade inflammation, as measured by CRP, plays a role in development of cancer, particularly of the lung, in those with stable CVD.
During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.
A single-center prospective PCI-registry showed an independent association of high residual inflammatory risk and adverse clinical outcomes in patients undergoing PCI with LDL-c ≤70 mg/dL at baseline.
EAS 2019 Paul Ridker discusses the positive effect of canakinumab on, in particular, non-small cell lung cancer incidence and mortality, as demonstrated in the CANTOS trial.
Bleeding on probing, increased probing pocket depth, caries or fillings in childhood were associated with increased IMT 27 years later, independent of cumulative exposure to CV risk factors.
This observational study showed prognostic value of IL-1β for acutely decompensated HF (ADHF) in those with high sST2 (IL-1 receptor) levels, and a meaningful correlation between IL-1β and sST2.